BTG Licenses Alzheimer's Compounds To Senexis And Co-Invests £1 Million With The Wellcome Trust

07-Feb-2006

BTG plc and Senexis Limited announced that BTG has exclusively licensed its novel inhibitors of amyloid-induced toxicity and neuroinflammation to Senexis. These compounds may be useful in the treatment of Alzheimer's disease and other amyloid-based diseases. BTG will receive milestones payments as the compounds progress though development and future royalties on eventual sales. The first milestones will be triggered by candidate selection and approval to commence clinical studies.

BTG and the technology transfer division of the Wellcome Trust also announced that they have each invested £500,000 into Senexis to enable the company to progress preclinical development of its small molecule Alzheimer's programmes. BTG and the Wellcome Trust provided initial funding of £1.4 million to Senexis in November 2002.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance